MedTrace Logo

Efficacy and Safety Study of SUNPG1622

NCT02980705 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2021-11-01

Study results available
· View outcomes & findings →

Summary

This is a randomized, double-Blind, placebo-controlled Phase 2a study to evaluate the efficacy and safety of SUNPG1622.

Conditions

  • Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis

Interventions

DRUG

SUNPG1622 I dose

Injection

DRUG

Placebo dose

Injection

Sponsors & Collaborators

  • Sun Pharmaceutical Industries Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-06
Primary Completion
2019-02-21
Completion
2019-09-03
FDA Drug
Yes

Countries

  • United States
  • Hungary
  • Poland
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02980705 on ClinicalTrials.gov